1171 results about "Tryptophan" patented technology

The invention discloses recombinant escherichia coli for inactivating or weakly expressing SPMB family inner membrane protein and application of the recombinant escherichia coli in production of L-amino acid. The invention relates to the technical field of gene engineering, and provides recombinant escherichia coli, and SPMB family inner membrane protein in the recombinant escherichia coli is inactivated or reduced in activity. According to the invention, the yjiG gene (coding gene of SPMB family inner membrane protein) in escherichia coli is knocked out, so that the expression intensity of the yjiG gene is weakened, and fermentation production strains of L-threonine, L-tryptophan, L-arginine and L-valine, which are more cost-effective, can be produced. The invention has important significance for improving the fermentation yield of bacteria, namely L-threonine, L-tryptophan, L-arginine and L-valine.

The invention discloses a formate dehydrogenase mutant and application thereof in catalytic synthesis of D-mannitol, and belongs to the technical field of bioengineering. According to the formate dehydrogenase mutant provided by the invention, the 18th-site glutamic acid of wild-type formate dehydrogenase with an amino acid sequence shown as SEQ ID NO.2 is mutated into proline, the 57th-site asparagine is mutated into glutamic acid, the 70th-site histidine is mutated into tryptophan, the 235th-site serine is mutated into threonine, and the 316th-site valine is mutated into threonine, so that the formate dehydrogenase mutant is high in enzyme activity and catalytic activity; the coenzyme circulation efficiency during the production of D-mannitol can be obviously improved, so that the yield of D-mannitol can be effectively improved. When the genetically engineered bacterium co-expressed by the formate dehydrogenase mutant and the mannitol dehydrogenase mutant is used for catalyzing 150 g / L fructose to produce D-mannitol, the yield of D-mannitol within 15 h can reach 140 g / L or above.

The invention discloses construction and optimization of a gene editing tool based on CRISPR (clustered regularly interspaced short palindromic repeats)-associated transsposases and application of the gene editing tool in escherichia coli, and belongs to the field of synthetic biology and gene engineering. According to the invention, an efficient gene editing system is established in Escherichia coli, and the burden of a MUSCULAR-CAST system on strains is reduced through element optimization; by eliminating the self-targeting effect, large-fragment (> 10k bp) target gene expression cassettes can be efficiently integrated, and the editing degree of the gene editing system is improved. According to the invention, a MUSCULAR-CAST gene editing system is used for constructing the chassis strains for producing 3-fucosyllactose, L-tryptophan, 2 '-fucosyllactose and neotetraose, so that the chassis strains have equivalent or higher expression yield compared with plasmids, and the growth condition is better or the conversion rate is higher.

The invention discloses application of a low-toxicity broad-spectrum antibacterial peptide taking WW as a symmetric center, WK is repeated twice and symmetrically distributed on two sides, WW is taken as the symmetric center to obtain an antibacterial peptide WKWKWWKWKW-NH2 (N2W2), and tryptophan at the C terminal and the N terminal of the N2W2 is replaced with leucine and / or isoleucine to obtain the antibacterial peptide. The antibacterial peptide can basically maintain the excellent antibacterial activity of the parent peptide, and the hemolytic activity of the antibacterial peptide is greatly reduced, so that the safety is improved. Wherein the antibacterial activity of IL-N2W2 is the highest, but the stability of IL-N2W2 needs to be improved, so that D-IL-N2W2 is obtained by carrying out D-type amino acid substitution on IL-N2W2. The D-IL-N2W2 keeps the high antibacterial activity and low toxicity of IL-N2W2, can still completely inhibit the growth of bacteria after being incubated with high-concentration trypsin or chymotrypsin, has great potential in the aspect of relieving the drug resistance of antibiotics, and has good application prospects in preparation of clinical antibacterial drugs.

The invention discloses a full D-type antibacterial peptide with high enzymolysis stability and broad-spectrum antibacterial activity and application thereof. The antibacterial peptide is obtained by sequentially and repeatedly arranging D-type tryptophan, D-type arginine and D-type lysine for four times and carrying out C-terminal amidation; the amino acid sequence of the gene is (D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-(D-Trp)-(D-Arg)-(D-Lys)-NH2, and is marked as DWRK-12. The antibacterial peptide shows broad-spectrum antibacterial activity and excellent stability, can effectively resist clinically separated multidrug resistant strains, and keeps high cell selectivity at the same time. Due to the characteristics, the antibacterial peptide has important application value in the aspect of developing novel antibacterial drugs, especially in the field of treatment of infection of multiple drug-resistant bacteria.

The invention relates to the field of polypeptide compositions, in particular to a polypeptide metal chelate and application thereof in the field of cosmetics, and the polypeptide metal chelate is formed by chelating a polypeptide compound and a metal ion compound. The structure of the polypeptide compound is [gamma-Glu] n-AA, n is greater than or equal to 1, and AA is selected from glycine, alanine, valine, leucine, isoleucine, methionine (methionine), proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, asparaginic acid, glutamic acid, lysine, arginine or histidine; the polypeptide chelated zinc prepared by the invention has remarkable oil control and anti-inflammatory effects, and can be compounded with other raw materials to form cosmetics with oil control and acne removal effects.

Provided is the use of a conjugated cholic acid, tryptophan-conjugated bile acids (TrpCA) or a TrpCA-producing strain for preventing and / or treating a metabolic disease. The present disclosure relates to the use of tryptophan-conjugated cholic acid or its producing bacteria strain in the preparation of a composition for preventing and / or treating a metabolic disease, or for promoting GLP-1 and / or insulin production. The inventors have discovered for the first time that the tryptophan-conjugated cholic acid can significantly promote the secretion of GLP-1 in both in vivo animal model and in vitro cell model, thereby reducing weight, lowering blood glucose and relieving symptoms of non-alcoholic fatty liver disease. Moreover, colonization of the selected probiotics can also have the same metabolic improvement effects.

There is provided the use of Lactobacillus paracasei or a afterbiogen in the preparation of a pharmaceutical composition or a food composition for the production of tryptophan-binding cholic acid. The Lactobacillus paracasei or the afterbiogen thereof can be used to prevent and / or treat metabolic diseases or to promote the production of GLP-1 and / or insulin, or to maintain blood glucose healthy levels, to maintain blood lipid health and / or to control fat in the body.

The invention provides application of combined cholic acid TrpCA and producing bacteria thereof in treating and preventing metabolic diseases. The present invention relates to the use of tryptophan-binding cholic acid or a producing bacterium thereof in the preparation of a composition for preventing and / or treating a metabolic disease or for promoting the production of GLP-1 and / or insulin. The inventor finds for the first time that tryptophan-bound cholic acid can remarkably promote secretion of GLP-1 on an in-vivo animal model and an in-vitro cell model, the effects of reducing weight, reducing blood sugar and relieving the symptoms of the non-alcoholic fatty liver disease are achieved, and the same metabolism improvement effect can also be achieved through planting of probiotics capable of generating cholic acid TrpCA.

The invention discloses a surface-enhanced tryptophan modified nanofiltration membrane as well as a preparation method and application thereof. Belongs to the field of water treatment membrane preparation. The invention aims to solve the technical problems of non-uniform pore size distribution and surface hydrophobicity of the conventional nanofiltration membrane. The method comprises the following steps: adding tryptophan into a piperazine water-phase solution, and carrying out interfacial polymerization with oil-phase trimesoyl chloride to prepare the tryptophan modified nanofiltration membrane. According to the preparation method, the diffusion rate of the piperazine monomer can be adjusted in the interfacial polymerization process by utilizing a similar surfactant structure of tryptophan, meanwhile, the tryptophan has hydrophilicity and can improve the hydrophilicity of the surface of an active layer, and the prepared modified nanofiltration membrane is reduced in molecular weight cut-off, improved in surface hydrophilicity and good in water resistance. The retention rate of organic micro-pollutants is improved, and meanwhile, good anti-pollution performance is achieved.

The invention relates to the technical field of biology, in particular to a method for synthesizing S-sulfo-L-cysteine through multi-enzyme cascade catalysis. The invention provides a new route for biosynthesis of S-sulfo-L-cysteine, and a test result shows that serine, AMP, sodium hexametaphosphate and sodium thiosulfate are used as substrates, and the S-sulfo-L-cysteine is synthesized by a one-step method. A crude enzyme liquid which contains serine kinase, polyphosphoric acid-AMP phosphotransferase and phosphoserine dependent type S-sulfo-L-cysteine synthetase in which the background of tryptophanase and glutaredoxin cells is knocked out is used for synthesizing the S-sulfo-L-cysteine, the steps are simple, the product yield is high, the cost is low, and the method has a relatively strong industrial application prospect.

The invention discloses a 3 '-phosphoadenosine-5'-phosphoryl sulfate synthetase mutant and an application of the 3 '-phosphoadenosine-5'-phosphoryl sulfate synthetase mutant. Compared with a wild enzyme amino acid sequence as shown in SEQ ID NO.1, the amino acid sequence of the 3 '-adenosine-5'-phosphoryl sulfate synthetase mutant has one or two mutations in the 101 site, the 207 site and the 560 site; preferably, phenylalanine at the 101 site is mutated into tryptophan; cysteine at the 207th site is mutated into glycine; phenylalanine at the 560th site is mutated into tryptophan. The invention also provides a synthesis method and application of the 3 '-adenosine-5'-phosphoryl sulfuric acid. The APS intermediate product inhibition effect of hPAPSS1 is relieved through a point mutation technology, the substrate affinity of hPAPSS1 to ATP is improved, and a mutant enzyme with a high PAPS conversion rate is obtained; and the bifunctional enzyme hPAPSS1 is synthesized by heterologous expression of PAPS in escherichia coli, so that the acquisition of the enzyme is simplified, and the synthesis efficiency of PAPS is improved.

The invention discloses construction and application of an escherichia coli L-tryptophan biosensor, and belongs to the technical field of bioengineering. The L-tryptophan biosensor provided by the invention comprises a mutated leader peptide fragment tnaC-tnaA, a promoter of the mutated leader peptide fragment tnaC-tnaA, a green fluorescent protein coding gene eGFP and a pTrc99a plasmid skeleton, a recombinant strain containing the L-tryptophan biosensor is cultured, the expression of green fluorescent protein in a culture solution is gradually enhanced along with the increase of the concentration of the L-tryptophan, and the fluorescence value of a unit cell shows better correlation when the concentration of the L-tryptophan is 0-1.5 g / L; therefore, when the biosensor is used for detecting the L-tryptophan in the fermentation liquor, the biosensor has the characteristics of simplicity in operation, sensitive response and high threshold value.

Soybean plants producing seeds and soybean seeds comprising increased protein content are provided. Also provided are soybean plants producing seeds and soybean seeds comprising increased amounts of essential amino acids such as methionine, tryptophan or lysine. Protein compositions having increased essential amino acids can be made from the soybean seeds. Additionally, methods for generating and using plants, seeds and protein compositions having increased protein content or increased amounts of essential amino acids are disclosed.

The invention discloses an ultrashort-sequence antibacterial peptide rich in lysine and tryptophan, an antibacterial peptide hydrogel and application of the ultrashort-sequence antibacterial peptide and the antibacterial peptide hydrogel. The preparation method comprises the following steps: combining lysine and tryptophan to obtain polypeptide containing five or six amino acids; then amidation is carried out on the C terminal of the polypeptide, fatty acid chain modification is carried out on the N terminal and side chain amino groups, the ultra-short sequence antibacterial peptide rich in lysine and tryptophan is obtained, and the antibacterial peptide has broad-spectrum antibacterial activity for resisting gram-positive and gram-negative bacteria. An antibacterial peptide micelle self-assembly experiment shows that C12-2KW can be self-assembled into stable hydrogel in a 7.17 mu M PBS (Phosphate Buffer Solution), the hydrogel internally has a compact net-shaped structure, can completely cover the peritoneal injury surface and physically isolate the peritoneal injury surface from surrounding tissues, and has a good effect on treating wound infection caused by MRSA (Methicillin-Resistant Staphylococcus Aureus); meanwhile, the compound has the effect of resisting intestinal wall and abdominal wall adhesion after an operation, is low in toxicity, has a very good application prospect in the aspect of preparing clinical antibacterial drugs, and is expected to become a candidate drug of a novel antibiotic.

The invention relates to the field of gene engineering, and particularly provides a PntB mutant for improving the yield of L-tryptophan, a genetically engineered bacterium containing the mutant as well as a construction method and application of the genetically engineered bacterium, aiming at the problem that NADPH (nicotinamide adenine dinucleotide phosphate) is insufficient in the production process of aromatic amino acid, especially L-tryptophan, pyridine nucleotide transhydrogenase beta subunit mutant PntB (A167T) is obtained through site-specific mutagenesis, and the PntB mutant PntB (A167T) is used for improving the yield of L-tryptophan. According to the present invention, the mutant is constructed, the genetically engineered bacterium containing the mutant is constructed, the genetically engineered bacterium is applied to L-tryptophan fermentation so as to promote the conversion of NADH to generate NADPH, the intracellular NADPH concentration is increased by 4.8 times, the L-tryptophan production ability of the genetically engineered strain BDP2 is increased by 38.8% compared with the initial strain BDX1, the L-tryptophan yield reaches 1.02 g / L, and the efficient synthesis of the L-tryptophan is finally achieved.

Provided here is use of Lacticaseibacillus paracasei or postbiotics thereof for the manufacture of a pharmaceutical or a food composition for generating a cholic acid conjugated to tryptophan. The Lacticaseibacillus paracasei or the postbiotics thereof can be used for preventing and / or treating a metabolic disease, or for promoting GLP-1 and / or insulin production, or for maintaining healthy blood glucose level, maintaining healthy lipid level and / or controlling body fat.

The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor.

The invention relates to the technical field of diagnosis markers and diagnosis methods for mental diseases of children and adolescents, in particular to a plasma metabolism diagnosis marker and diagnosis system for depression of children and adolescents. The plasma metabolism diagnosis marker comprises at least one of cyclic adenosine monophosphate, methylpyridine, unsaturated undecylenyl carnitine, histidine, prolyl hydroxyproline, tryptophan and glucuronic acid. According to the scheme, non-target metabonomics data is analyzed, and seven candidate diagnostic markers for depression of children and adolescents are screened and determined from common differential metabolites. Then, through targeted metabonomics research, diagnostic markers and combinations thereof with ideal diagnostic effects are determined, and then a diagnostic model is constructed. And a sex factor is also incorporated into the diagnosis model, so that the diagnosis effect is further improved. According to the technical scheme, the technical problem that in the prior art, reliability and popularization potential of depression plasma metabolism biomarkers of children and adolescents are not ideal can be solved, and the depression plasma metabolism biomarkers have ideal popularization and application prospects.

The present invention provides a 5-hydroxytryptophan production strain and a construction method and application thereof. The strain has a clear genetic background and is effective in producing 5-hydroxytryptophan. E.coli HTP11 Subtilis subtilis spores pureF bsu K316Q Mutated gene, upregulated strain E.coli HTP11 of guaB , guaA , gmk , ndk The transcription level of the gene was increased by heterologous introduction of the gapX Gene, missing aromatic amino acid transporter serB , tnaB , aroP Gene, up-regulated inner membrane efflux transporter yhjV The transcription level of the gene was increased and electroporated into the pTm-serB plasmid, which could stably provide 5-hydroxytryptophan, the direct precursor of 5-hydroxytryptophan, and had a high efficiency of 5-hydroxytryptophan output.

An engineered bacterium for improving tryptophan yield, a construction method therefor, and a use thereof. A strain capable of tolerating a high concentration of tryptophan was obtained by screening. Genome sequencing and protein sequence analysis of the strain revealed that some proteins in the strain had undergone point mutations, and these mutants can improve the tryptophan yield. In order to further improve the tryptophan yield, modifications are made to a protein sequence expressed by a fadR gene or a protein sequence expressed by a pepD gene in a starting bacterium. Such modifications enable the obtained engineered bacterium to have a higher tryptophan yield than the starting bacterium. In the case of large-scale production, in a 5 L fermentation tank, the tryptophan yield can reach 62.38±5.80 g / L, and the sugar-to-acid conversion rate can reach 24.1%. Compared with the original bacterium, the tryptophan yield is increased by 1.48 folds, and the sugar-to-acid conversion rate is increased by 1.26 folds. The biological material and the use thereof relate to the technical field of molecular biology and have wide practical application value.

The invention discloses a gelator and a preparation method and application thereof, the structural formula of the gelator is # imgabs0 #, R1 is a side chain group connected to an amino acid central carbon atom except an amino group, a carboxyl group and a hydrogen atom; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; the amino acid is selected from one of glycine, alanine, valine, leucine, isoleucine, methionine, proline, tryptophan, serine, tyrosine, cysteine, phenylalanine, asparagine, glutamine, threonine, aspartic acid, glutamic acid, lysine, arginine, histidine, selenocysteine and pyrrole lysine; r2 is alkyl with the carbon atom number of 16 to 19; and R3 is 9-fluorenyl methoxy carbonyl group or t-butyloxycarbonyl group. The gelator has a hydrophobic long alkyl tail chain, can spontaneously gather and assemble into a three-dimensional network structure through hydrogen bonds, pi-pi interaction and hydrophobic force, and fixes an oil phase in an oil solvent or an oil-water mixture in an effective manner to form high-strength gel.

The invention belongs to the technical field of microorganisms, and particularly relates to stenotrophomonas maltophilia yg3 and application thereof. The invention discloses stenotrophomonas maltophilia yg3, and the preservation number of the stenotrophomonas maltophilia yg3 is CGMCC (China General Microbiological Culture Collection Center) No.34131. The stenotrophomonas maltophilia yg3 disclosed by the invention has the capability of efficiently synthesizing indoleacetic acid (IAA), and the IAA yield of 98.10 mg / L can be realized without optimization in an NB culture medium containing 5mM L-tryptophan, which is obviously higher than that of other wild strains. Moreover, the stenotrophomonas maltophilia yg3 has a remarkable growth promoting effect on plants (such as hot peppers), pot experiments show that the stenotrophomonas maltophilia yg3 can remarkably increase the number of effective leaves, the plant height and the biomass of the hot peppers, and the stenotrophomonas maltophilia yg3 can be applied to the field of microorganisms. Particularly, the method has important application value in the fields of microbial plant growth promoters and green synthesis of IAA (indoleacetic acid).

The invention discloses a method for detecting soil active organic carbon based on fluorescence spectrometry, and belongs to the technical field of soil detection. The method comprises the following steps: sequentially drying, sieving and grinding fresh soil to obtain a soil sample, and sequentially performing active organic carbon extraction, purification, decoloration and pH regulation on the soil sample to obtain a soil liquid to be detected. The method comprises the following steps: adding fluorescein into a soil liquid to be detected to form a soil internal standard detection liquid, obtaining a soil fluorescence spectrum through three-dimensional fluorescence spectrum scanning, carrying out background deduction and correction coefficient correction, and calculating the active organic carbon concentration of the soil by using tryptophan, tyrosine and SMP fluorescence concentration standard curves. According to the method, an internal standard method is combined with a fluorescence spectrum technology, and through multi-step sample pretreatment and spectrum correction, the detection accuracy and the anti-interference capability are improved, the active organic carbon concentration of the soil can be rapidly and accurately determined, and an effective means is provided for soil carbon cycle research and quality evaluation.

The invention provides a preparation method of an efficient selective antagonist BQ-788, and relates to the technical field of preparation of antagonists. A solid-liquid combination method is adopted for synthesis, due to the fact that dimethyl dialkanoate on a side chain of tryptophan (DTrp) is difficult, Fmoc-DTrp (CO2Me)-OH is obtained through liquid-phase synthesis, p-methoxybenzyl is selected for protecting carboxyl in the synthesis process, the carboxyl can be removed through trifluoroacetic acid subsequently, and the risk that an indole ring of tryptophan is reduced due to hydrogenation can be successfully avoided. According to the present invention, by using the solid phase synthesis method, the fragment can be rapidly and efficiently obtained, the racemization problem during the condensation process can be effectively avoided, the urea is formed on the solid phase, the operation is simple and convenient, the hydrogen and the diphosgene are not used during the preparation process, the production is safe, the obtained product has characteristics of high yield and high purity, and the preparation steps are less.

The invention discloses an early diagnosis and early screening kit for joint detection of Parkinson's disease and application of the kit, and relates to the technical field of medical treatment. The kit is used for combined detection of three proteins, namely alpha synuclein (alpha-Syn), tyrosine 3-monooxygenase / tryptophan 5-monooxygenase activated protein zeta (YWHAZ) and myosin light chain 6 (Myl6), immunochromatography, chemiluminescence and other methods and a double-antibody sandwich method are adopted, the diagnosis efficiency of the YWHAZ protein is prominent, the AUC reaches 0.96, and the detection sensitivity is high. The AUC of Myl6 is 0.92, the AUC of alpha-Syn is 0.82, the joint detection AUC is up to 0.98, the kit is newly added with a time-resolved fluorescence immunochromatography technology, low-background and high-sensitivity detection is realized through a lanthanide-labeled antibody, the change of related protein expression level can be detected in the early stage of Parkinson's disease, early screening and diagnosis are realized, and the kit has the advantages of high specificity, joint detection up to 95%, high sensitivity, high sensitivity and the like. The joint detection reaches 96%, the operation is simple and convenient, and the sample requirement is low.

The invention discloses an application of inulin in preparation of a medicine for treating polycystic ovarian syndrome, especially the polycystic ovarian syndrome caused by high fat diet. Starting from the pathogenesis of the PCOS, research is carried out in the direction of'regulating host-intestinal dialogue by dietary fibers, promoting a tryptophan-quinolinic acid metabolic pathway to enhance an NAD + de novo synthesis pathway and improving PCOS oxidative stress and insulin resistance ', pathophysiology of the PCOS is researched from a brand new perspective, and the pathogenesis of a patient suffering from the PCOS is comprehensively researched in combination with metabonomics. And a new thought and a new target spot are provided for subsequent treatment.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention relates to the field of gene engineering, in particular to a phenolic acid decarboxylase mutant and application thereof. According to the invention, tryptophan at the 30th site of phenolic acid decarboxylase PADCs from Clostridium sp.DSM 8431 is mutated into leucine, and tyrosine at the 136th site of the phenolic acid decarboxylase PADCs is mutated into tryptophan, so that the phenolic acid decarboxylase mutant is obtained. The phenolic acid decarboxylase mutant can catalyze decarboxylation reaction of p-coumaric acid to synthesize p-hydroxystyrene; and hydrocarbonate can also be used as a carboxyl source to catalyze carboxylation reaction of p-hydroxystyrene to synthesize p-coumaric acid. The phenolic acid decarboxylase PADCs has the enzyme activity characteristics of excellent temperature stability and acetonitrile stability, still retains more than 80% of decarboxylase activity after being incubated for 2 hours at 55 DEG C, still retains about 36% of decarboxylase activity after being incubated for 2 hours in acetonitrile with the volume fraction of 50%, can remarkably improve the yield of p-coumaric acid, can reach 13.05 mM when the substrate concentration is 80 mM, and is improved by 74% compared with original phenolic acid decarboxylase PADCs; the method has a wide industrial application prospect and CO2 fixation potential.

The invention discloses weight-reducing and blood-sugar-reducing meal replacement powder for increasing satiety and a preparation method thereof, and belongs to the technical field of meal replacement powder. Comprising resistant starch, bio-enzyme modified whey protein concentrate, bio-enzyme modified soybean protein isolate, bio-enzyme modified white kidney bean hydrolyzed protein, oat fiber powder, nano emulsion milk powder, mogroside, chitosan, inulin, konjac powder, pumpkin seed powder, a cactus extract, a griffonia simplicifolia seed extract and a Chinese waxgourd peel extract. Through the synergistic effect of multiple components and multiple processes, the obvious effects of satiety, weight loss and blood sugar reduction are achieved. 5-hydroxytryptophan in the griffonia seed extract can regulate satiety center and delay hunger sensation; dietary fibers such as the resistant starch and the inulin absorb water and swell in intestinal tracts to form high-viscosity gel, so that the satiety is further enhanced, and the eating frequency and the eating amount are reduced. A low-calorie and high-protein formula is combined with components such as tartronic acid in the Chinese waxgourd peel extract and the cactus extract, so that fat catabolism is accelerated, and fat synthesis is inhibited.